Fig. 3: BCAT1 decreases cisplatin sensitivity by mTOR-mediated autophagy. | Cell Death & Disease

Fig. 3: BCAT1 decreases cisplatin sensitivity by mTOR-mediated autophagy.

From: BCAT1 decreases the sensitivity of cancer cells to cisplatin by regulating mTOR-mediated autophagy via branched-chain amino acid metabolism

Fig. 3

A Western blot analysis of BCAT1, p62, and LC3-I/II protein levels in Hela cells overexpressing BCAT1. B Western blot analysis of BCAT1, p62, and LC3-I/II protein levels in BCAT1 knockdown HepG2 cells. C The protein levels of BCAT1, mTOR, p70S6K, and 4E-BP1 and their phosphorylated counterparts in Hela cells overexpressing BCAT1. D The protein levels of BCAT1, mTOR, p70S6K, 4E-BP1 and their phosphorylated counterparts in BCAT1 knockdown HepG2 cells. E The protein levels of BCAT1, mTOR, p70S6K, 4E-BP1 and their phosphorylated counterparts and LC3-I/II in HepG2 or BCAT1 knockdown HepG2 cells treated with cisplatin (10 μM). F Representative image of HepG2 cells transfected with pCMV-mCherry-GFP-LC3B. The cells were treated with cisplatin (10 μM) or gabapentin (5 mM) alone or together for 24 h. Scale bars: 25 μm. G, H Hela cells overexpressing BCAT1 were treated with cisplatin (20 μM) alone or in combination with 20 μM CQ or 2 mM 3-MA for 24 h. Cell viability was assessed by CCK-8 assays. (I) BCAT1 knockdown HepG2 cells were treated with cisplatin (10 μM) alone or plus with rapamycin (100 nM) for 24 h. Cell viability was assessed by CCK-8 assays. Vec, empty vector; Ctrl, control. Three independent experiments were performed. ns, not significant. *P < 0.05, **P < 0.01.

Back to article page